“…Specifically, the enzyme positively regulates activation of macrophages (8,9,35), microglia (7,36), granulocytes (37), lymphocytes (6,13,14), as well as TNF-␣-challenged endothelial cells (38). Also, parp-1 null mice are resistant to endotoxic shock (39), and PARP-1 inhibitors provide protection in models of pleuritis (40), arthritis (41), asthma (42), colitis (43,44), allergic encephalomyelitis (6,15,45), and other autoimmune disorders (46). In this context, the present findings point to the negative regulation of DCs by PARP-1 inhibitors as a key mechanism through which this class of drugs suppresses the inflammatory response.…”